Descriptive Comparison of the Efficacy and Safety of OnabotulinumtoxinA for Headache Prophylaxis in Adult Chronic Migraine Patients from Two Long-term, Multicenter Studies: COMPEL vs. PREEMPT

被引：0
|
作者：
Aurora, S. [1 ]
Stark, R. [2 ,3 ]
Reppine, A. [4 ]
Adams, Manack A. [4 ]
Blumenfeld, A.
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Monash Univ, Clayton, Vic 3800, Australia
[3] Alfred Hosp, Melbourne, Vic, Australia
[4] Allergan Pharmaceut Inc, Irvine, CA USA
来源：
HEADACHE | 2015年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PF18
引用
收藏
页码：142 / 142
页数：1
相关论文
共 50 条
  • [41] LONG-TERM EFFICACY OF PCI VS. CABG FOR PATIENTS WITH MULTIPLE CORONARY CHRONIC TOTAL OCCLUSIONS
    Zhang Jian
    Han Yaling
    HEART, 2013, 99 : E170 - E170
  • [42] LONG-TERM EFFICACY OF PCI VS. CABG FOR PATIENTS WITH MULTIPLE CORONARY CHRONIC TOTAL OCCLUSIONS
    Zhang Jian
    Han Ya-Ling
    Jing Quan-Min
    Wang Xiao-Zeng
    Ma Ying-Yan
    Wang Geng
    Wang Bin
    HEART, 2013, 99 : A43 - A43
  • [43] Long-term safety and efficacy of pegunigalsidase alfa: A multicenter extension study in adult patients with Fabry disease
    Hughes, Derralynn
    Gonzalez, Derlis
    Maegawa, Gustavo
    Bernat, John
    Holida, Myrl
    Giraldo, Pilar
    Atta, Mohamed
    Chertkoff, Raul
    Alon, Sari
    Almon, Einat B.
    Rocco, Rossana
    Goker-Alpan, Ozlem
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S58 - S58
  • [44] Long-term safety and efficacy of pegunigalsidase alfa: A multicenter extension study in adult patients with Fabry disease
    Gonzalez, Derlis
    Maegawa, Gustavo
    Bernat, John
    Holida, Myrl
    Giraldo, Pilar
    Atta, Mohamed
    Chertkoff, Raul
    Alon, Sari
    Almon, Einat
    Rocco, Rossana
    Goker-Alpan, Ozlem
    GENETICS IN MEDICINE, 2022, 24 (03) : S91 - S91
  • [45] Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy (vol 8, 586, 2017)
    Guerzoni, Simona
    Pellesi, Lanfranco
    Baraldi, Carlo
    Cainazzo, Michela Maria
    Negro, Andrea
    Martelletti, Paolo
    Pini, Luigi Alberto
    FRONTIERS IN NEUROLOGY, 2018, 9
  • [46] Treatment responses to erenumab in onabotulinumtoxinA-refractory chronic migraine: Long-term real-world experience from a specialist headache centre
    Cheng, Fan
    Tang, Ker
    Wan, Shunwei
    Hu, Weihai
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 227 - 227
  • [47] Long-Term Efficacy of Fremanezumab in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
    Lipton, R. B.
    Cohen, J. M.
    Yang, R.
    Seminerio, M. J.
    Campos, V. Ramirez
    Singh, R. B. Walker
    Ailani, J.
    HEADACHE, 2019, 59 : 101 - 102
  • [48] Long-Term Efficacy of Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification
    Lipton, Richard
    Cohen, Joshua
    Yeung, Paul P.
    Yang, Ronghua
    Seminerio, Michael
    Campos, Verena Ramirez
    Singh, Rashmi Halker
    Ailani, Jessica
    NEUROLOGY, 2019, 92 (15)
  • [49] Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
    Yang, Ai Yu
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (01) : 21 - 28
  • [50] Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety
    Boudreau, Guy P.
    Grosberg, Brian M.
    McAllister, Peter J.
    Lipton, Richard B.
    Buse, Dawn C.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2015, 8 : 79 - 86
12345